Insights Into Hepatocellular Carcinoma (HCC)
Perspectives on current treatment practice attitudes toward therapy of unresectable advanced hepatocellular carcinoma (HCC), recently introduced and upcoming agents
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center, Phoenix, AZ
More information
- Virtual Series
- Oregon, Washington
More Information
- Virtual Series
- California
More Information
- Virtual Series
- Hawaii, Southern California, Phoenix
More Information
- Virtual Series
- Denver and Kansas City
More Information
- Virtual Series
- Houston, San Antonio, South Texas
More Information
- Virtual Series
- Dallas
More Information
- Virtual Series
- Florida, Georgia, North Carolina, South Carolina
More Information
- Virtual Series
- New York, Boston
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of hepatocellular carcinoma
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors will comprise 10–15 medical oncologists representative of each region
